ARS Pharmaceuticals (SPRY) Net Margin (2022 - 2025)
ARS Pharmaceuticals' Net Margin history spans 4 years, with the latest figure at 147.63% for Q4 2025.
- For Q4 2025, Net Margin fell 20771.0% year-over-year to 147.63%; the TTM value through Dec 2025 reached 212.92%, down 21488.0%, while the annual FY2025 figure was 203.25%, 21223.0% down from the prior year.
- Net Margin for Q4 2025 was 147.63% at ARS Pharmaceuticals, up from 163.66% in the prior quarter.
- Across five years, Net Margin topped out at 60.08% in Q4 2024 and bottomed at 206030.0% in Q2 2023.
- The 4-year median for Net Margin is 1061.19% (2024), against an average of 25890.08%.
- The largest annual shift saw Net Margin plummeted -20466276bps in 2023 before it skyrocketed 20296200bps in 2024.
- A 4-year view of Net Margin shows it stood at 3507.94% in 2022, then crashed by -5773bps to 206030.0% in 2023, then skyrocketed by 100bps to 60.08% in 2024, then plummeted by -346bps to 147.63% in 2025.
- Per Business Quant, the three most recent readings for SPRY's Net Margin are 147.63% (Q4 2025), 163.66% (Q3 2025), and 302.95% (Q2 2025).